ライフサイエンスコーパス: kinase domain

1 conventional Src inhibitors that target the kinase domain.

2 ve because of secondary mutations in the Kit kinase domain.

3 d and inhibit a constitutively dimerized PKR kinase domain.

4 for a protein isoform containing a truncated kinase domain.

5 ry regulatory domain but retaining an intact kinase domain.

6 360) within the activation loop of the HIPK2 kinase domain.

7 (Thr-172) within the activation loop of its kinase domain.

8 sense mutations that are enriched around the kinase domain.

9 is reduced upon in vitro acetylation of its kinase domain.

10 rylated Ser-966 motif downstream of the ASK1 kinase domain.

11 lates catalytically important regions of the kinase domain.

12 involving SGK1 and a functioning TRPM7 alpha-kinase domain.

13 able ion channel fused to a C-terminal alpha-kinase domain.

14 toylated at a conserved site adjacent to its kinase domain.

15 g coordinated motions that spread across the kinase domain.

16 l of ATP2B4 and high expression of the PRKCA kinase domain.

17 cted with the C-terminus of LRRK2, including kinase domain.

18 se node residues appear in both lobes of the kinase domain.

19 b developed because of a mutation in the ALK kinase domain.

20 Ras of complex proteins (Roc) G-domain and a kinase domain.

21 of the juxtamembrane region proximal to the kinase domain.

22 includes a juxtamembrane (JM) sequence and a kinase domain.

23 ocess facilitated by a docking groove in the kinase domain.

24 a highly conserved PIP box motif within the kinase domain.

25 ve site and the allosteric pocket in the Abl kinase domain.

26 nt (IC) and activates NEK8 by binding to its kinase domain.

27 domain, transmembrane domain and cytoplasmic kinase domain.

28 binding of the 1R,2S enantiomer to the PLK4 kinase domain.

29 ion-specific structural variances in the ALK kinase domain.

30 mechanism mediated by a linker (L1) near the kinase domain.

31 while binding to the ATP binding site in the kinase domain.

32 servation of features within their histidine kinase domain.

33 phosphorylating downstream proteins via its kinase domain.

34 tains a pseudo kinase in place of a tyrosine kinase domain.

35 s the N-terminal region and a portion of the kinase domain.

36 ceptor with an extracellular wall-associated kinase domain.

37 ase (ILK); i.e., viral ORF119L lacks the ILK kinase domain.

38 and WT EGFR differ in structure outside the kinase domain.

39 ting primarily of the intracellular tyrosine kinase domain.

40 e N- and C-lobes facilitating closure of the kinase domain.

41 ation domain (AF-1) thereby masking the TAK1 kinase domain.

42 hosphorylation at His(183) in its C-terminal kinase domain.

43 r-348 to an allosteric binding pocket on the kinase domain.

44 cs, kinetics, and accessible states of BTK's kinase domain.

45 sphorylated, but not unphosphorylated, IRAK4 kinase domain.

46 ATP-binding site (helices H9 and H11) of the kinase domain.

47 redundant, as they share a highly conserved kinase domain.

48 h the ATP-binding site of the CKI1 histidine kinase domain.

49 thout affecting the overall structure of the kinase domain.

50 cine-serine rich (GS) domain adjacent to the kinase domain.

51 including the coding sequence for the entire kinase domain.

52 e find that TRPM7 regulates SOCE through its kinase domain.

53 hers spread between the N and C lobes of the kinase domain.

54 ity via phosphorylation of sites outside the kinase domain.

55 isoforms, which consist of SH3 and guanylate kinase domains.

56 l solenoid tightly packs against the FAT and kinase domains.

57 tly contact head-to-head through the FAT and kinase domains.

58 cs simulations of their fully phosphorylated kinase domains.

59 b is a potent inhibitor of both ROS1 and ALK kinase domains.

60 up D of BEACH-domain proteins, which possess kinase domains.

61 , which promotes transphosphorylation of the kinase domains.

62 ucts and compared the tails with the ordered kinase domains.

63 ile retaining the transmembrane and tyrosine kinase domains.

64 d fibronectin domains and one or two protein kinase domains.

65 ium exchange behavior when compared with the kinase domains.

66 gene FASTKD2 (fas-activated serine/threonine kinase domains 2; rs7594645-G) with better memory perfor

67 a cysteine in the hinge region of the EphB3 kinase domain, a feature that is not shared with any oth

68 is essential for signal transduction to the kinase domain, a process for which Arg-204 is important.

69 JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is pr

70 nts, which reveal a structural mechanism for kinase domain activation in SHK.

71 ty has been enigmatic, and only recently has kinase domain activity been shown to be crucial for thei

72 -fold symmetry of the ECD, the intracellular kinase domains adopt an asymmetric dimer arrangement, in

73 ompound 25 shows 24 h occupancy of the PDGFR kinase domain, after a single i.t. dose and has efficacy

74 metric dimer of kinase domains, in which one kinase domain allosterically activates the other.

75 terminal fragment, p50 N-LOK, containing the kinase domain and a C-terminal fragment, which is furthe

76 r protein kinase that contains an N-terminal kinase domain and a C-terminal regulatory region consist

77 e traced to ancestral members that contain a kinase domain and a calmodulin-like domain.

78 RbkR proteins are composed of the riboflavin kinase domain and a DNA-binding winged helix-turn-helix-

79 UPF1 is recruited to the SMG-1 kinase domain and C-terminal insertion domain, inducing

80 it towards the hub interface, away from the kinase domain and calmodulin, thus unlocking the ability

81 large, multidomain protein which contains a kinase domain and GTPase domain among other regions.

82 tion of conserved amino acid residues in the kinase domain and impaired kinase activity.

83 ads to activation of the CERK1 intracellular kinase domain and induction of plant innate immunity in

84 s the E2 conformation, thus exposing the Src kinase domain and its active site Tyr-418 for activation

85 n of intramolecular interactions between the kinase domain and its N-terminal regulatory region indep

86 Interaction between kinase domain and regulatory light chain (RLC) substrate

87 ligand recognition and communication to the kinase domain and reveal the sensitivity of the system t

88 at aspartic residue 332, located between the kinase domain and the coiled-coil regulation domain.

89 nase active site that uses residues from the kinase domain and the juxtamembrane region.

90 terface formed between the large lobe of the kinase domain and the regulator of G protein signaling h

91 l features that distinguish the ROS1 and ALK kinase domains and contribute to differences in binding

92 terface between the Src homology 2 (SH2) and kinase domains and to the phosphotyrosine-binding site o

93 V mutations, which are located within ERK3's kinase domain, and are shown to exist in several cancers

94 in the extracellular domain, Delta736 in the kinase domain, and C300stop in the extracellular domain,

95 s activation status, the conformation of its kinase domain, and clinically relevant inhibitors.

96 ains, autophosphorylation of the cytoplasmic kinase domains, and conformational changes to the cytopl

97 2 protein contains nonoverlapping GTPase and kinase domains, and mutation in either domain can cause

98 cles leads to a peculiar phenomenon in which kinase domains appear to be trapped between stacks of li

99 o distinct ligand binding modes and a unique kinase domain architecture that has not been observed pr

100 Mutations in the EGFR kinase domain are implicated in non-small-cell lung canc

101 that mutations in the N-terminal end of the kinase domain are more disruptive of protein function.

102 n sites in the tail that are proximal to the kinase domain are phosphorylated in only one subunit.

103 igand-bound dimers, in which the majority of kinase domains are activated cooperatively, thereby boos

104 Abl's SH3, SH2, and tyrosine kinase domains are joined via a linker to an F-actin-bin

105 While most kinase domains are ordered independently, approximately

106 al infection, and this requires a functional kinase domain, as well as a functional dsRNA-binding dom

107 a interacts physically with Atg1 through its kinase domain, as well as with Atg6 and Vps34.

108 activating mutations are present within its kinase domain, as with the F1174L mutation.

109 Besides a conserved kinase domain at the C terminus, ATM contains three othe

110 Surrogates for the LRRK2 kinase domain based on checkpoint kinase 1 (CHK1) mutant

111 uencing, only five distinct mutations in the kinase domain behave as dominant-negative mutations in z

112 tight inhibitory complex with a primed aPKC kinase domain, blocking substrate access.

113 uptake requires PDPK1 phosphorylation of the kinase domain but not mTORC2 phosphorylation of the HM d

114 anaphase promotion function required BUB-1's kinase domain, but not its kinase activity, and this fun

115 We further demonstrated that the kinase domain, but not the kinase function, of S6K1 was

116 d bifunctional channels to contain their own kinase domains, but how these channel-kinases are regula

117 ched on through allosteric activation of one kinase domain by another, and we show that if this is re

118 osed state, where structural elements of the kinase domain C-tail are aligned to form novel interacti

119 1 and three missense mutations affecting the kinase domain (c.208G>C [p.Glu70Gln], c.299T>A [p.Val100

120 of the MET gene, and mutations in the c-Met kinase domain can activate signaling pathways that contr

121 The N-terminal LOK kinase domain can then access a site 40 residues distal

122 tyrosine kinases with a tandem pseudokinase-kinase domain configuration, where the pseudokinase doma

123 urified recombinant full-length proteins and kinase domain constructs differed substantially in phosp

124 omain and membrane-associated guanylate-like kinase domain-containing protein 3; membrane protein, pa

125 ssion of EC markers, including: 1) CD105; 2) kinase domain-containing receptor; and 3) Ulex europaeus

126 ed 2 binding surfaces on the beta4 guanylate kinase domain contributing to a 156 +/- 18 microM Kd int

127 n swapping experiments showed that the RIPK4 kinase domain could be converted to a dual-specificity k

128 rame kinase fusion transcripts that retain a kinase domain (CPQ-PRKDC, CAPZA2-MET, and VGLL4-PRKG1).

129 laced, resulting in the rearrangement of the kinase domain-dimer interface and a rotation of the RNas

130 lts demonstrate that imatinib binding to the kinase domain effects dynamics of proline-rich or phosph

131 at combines an ion channel with an intrinsic kinase domain, enabling it to modulate cellular function

132 ed understanding of which amino acids in the kinase domain encode substrate specificity, the so-calle

133 Vps15 intertwine in one arm, where the Vps15 kinase domain engages the Vps34 activation loop to regul

134 l adhesion kinase targeting domain (FAT) and kinase domains enhanced mTORC1 kinase activity, decrease

135 nding linear motif (residing in a disordered kinase domain extension) and the ERK2 "docking" groove p

136 kinase activation process in which the IRAK4 kinase domain first homodimerizes in the Myddosome, lead

137 re of LegK4(1-445) reveals a eukaryotic-like kinase domain flanked by a novel cap domain and a four-h

138 Additionally, the IRAK1 kinase domain forms heterodimers with the phosphorylated

139 the prevailing assumption has been that the kinase domain fragment (deltaKD) freed from autoinhibito

140 Its kinase domain functions in allostery not catalysis, and

141 The BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) conf

142 (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechani

143 nding partners for a number of this family's kinase domains have been identified, the catalytic neces

144 ort the crystal structure of the human IRAK1 kinase domain in complex with a small molecule inhibitor

145 first structural characterization of the Axl kinase domain in complex with a small-molecule macrocycl

146 e the x-ray co-crystal structures of the COT kinase domain in complex with two ATP-binding site inhib

147 we report a biochemical analysis of the ASK1 kinase domain in conjunction with its N-terminal thiored

148 Due to its inhibition of the Abl kinase domain in the BCR-ABL fusion protein, imatinib is

149 SH3-SH2 domains perturb the dynamics of the kinase domain in the context of the full length protein.

150 addition, PUB13 could ubiquitinate the LYK5 kinase domain in vitro.

151 The kinase domains in the Mec1.Ddc2 dimer are located in clo

152 s on the formation of an asymmetric dimer of kinase domains, in which one kinase domain allostericall

153 Conditional MET kinase domain inactivation (Met(fl/fl); Wnt1Cre+) caused

154 terms of crystal structures of the inactive kinase domain, including two new ones presented here.

155 achieved pharmacologically by small molecule kinase domain inhibitors.

156 The GFS12 kinase domain interacted specifically with the pleckstri

157 introducing point mutations in the GRK5 RHD-kinase domain interface, we show with both in silico and

158 tion by bringing the thioredoxin-binding and kinase domains into close proximity.

159 While the IRAK4 kinase domain is capable of homodimerization in the unph

160 hosphorylated state, we found that the IRAK1 kinase domain is constitutively monomeric regardless of

161 These findings suggest that RIPK2's kinase domain is functionally unique compared with other

162 t a conserved lysine residue in the putative kinase domain is important for PCRK1 function.

163 The overall conformation of the GRK5 kinase domain is similar to that of a previously determi

164 the three members of the TAM family, the Axl kinase domain is the only one that has so far eluded str

165 The C-terminal tail (C-tail) of AGC kinase domains is a highly conserved feature that is div

166 entral hub complex, while positioning of the kinase domains is highly flexible, revealing dynamic hol

167 Furthermore, we show that Kin2 kinase domain itself is sufficient to activate the UPR,

168 racterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase d

169 2+-regulated kinases, by derepression of the kinase domain (KD).

170 ce conformational changes to wild-type B-Raf kinase domain leading to heterodimerization with C-Raf c

171 ng protein kinase 3 (RIPK3) or mixed lineage kinase domain like (MLKL), two core proteins of the necr

172 threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like (MLKL) and generally manifests with m

173 t RIP3-dependent activation of mixed lineage kinase domain-like (MLKL) leading to necroptosis.

174 f necrosis, is executed by the mixed lineage kinase domain-like (MLKL) protein, which is triggered by

175 otal levels of RIP1, RIP3, and mixed lineage kinase domain-like (MLKL) proteins were increased follow

176 g protein kinase-3 (RIPK3) and mixed lineage kinase domain-like (MLKL) proteins.

177 otein kinase 3 (RIPK3) and the mixed lineage kinase domain-like (MLKL) pseudokinase.

178 ion and phosphorylation of the mixed lineage kinase domain-like (MLKL) pseudokinase.

179 ivates the downstream effector mixed lineage kinase domain-like (MLKL) to induce necroptosis.

180 protein kinase (RIPK) 1/3- and mixed-lineage kinase domain-like (MLKL)-dependent necroptosis.

181 e 3 (RIPK3) and its substrate, mixed lineage kinase domain-like (MLKL).

182 eam effector, the pseudokinase mixed lineage kinase domain-like (MLKL).

183 y leading to the activation of mixed lineage kinase domain-like and plasma membrane permeabilization.

184 id not increase phosphorylated mixed lineage kinase domain-like in RIP3(-/-) mice.

185 ase 3 (RIP3) and its substrate mixed-lineage kinase domain-like protein (MLKL) are core regulators of

186 forms of programmed necrosis [mixed lineage kinase domain-like protein (MLKL) in necroptosis and gas

187 onstrate that the pseudokinase mixed lineage kinase domain-like protein (MLKL) participates in hepato

188 The expression level of mixed lineage kinase domain-like protein (MLKL), a key downstream comp

189 of necroptosis, phosphorylated mixed-lineage kinase domain-like protein (MLKL), was detected in CD11b

190 nstrated that the pseudokinase mixed lineage kinase domain-like protein (MLKL), which plays a key rol

191 e-3 (RIPK3) phosphorylation of mixed-lineage kinase domain-like protein (MLKL), which results in disr

192 ions, RIPK3 phosphorylates the mixed lineage kinase domain-like protein (MLKL), which then disrupts c

193 S, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL).

194 teracting proteins 1 and 3 and mixed lineage kinase domain-like protein necroptotic signaling with th

195 ed by levels of phosphorylated mixed lineage kinase domain-like protein.

196 lasma membrane localization of mixed lineage kinase domain-like pseudokinase (MLKL).

197 PK3, and a pseudo-kinase MLKL (Mixed Lineage Kinase domain-Like) associated in a multi-protein comple

198 sis, as well as phosphorylated mixed lineage kinase domain-like, an effector of necroptotic cell deat

199 ally lead to the activation of mixed lineage kinase domain-like.

200 our-point one, ezrin, radixin, moesin (FERM)-kinase domain linker, which contains autophosphorylation

201 bility and greater dynamic nature of the Axl kinase domain may account for its poor crystallizability

202 lytic and regulatory architecture within the kinase domain may be a crucial element in transmitting i

203 with different phenotypes than those in the kinase domain (MEN2B-like mutations).

204 These findings identify ATM kinase-domain missense mutations as a potent oncogenic e

205 constitutive PDGFRbeta signaling caused by a kinase domain mutation (D849V) develop lethal autoinflam

206 pproximately 50% of TKI-resistance caused by kinase domain mutations and the remainder due to unknown

207 able ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.

208 Kinase domain mutations are detectable in 25% to 37% of

209 resistance due to acquisition of ROS1 or ALK kinase domain mutations has been observed clinically, sp

210 myeloid leukemia, the emergence of tyrosine kinase domain mutations has historically been the domina

211 on-small cell lung cancer (NSCLC), including kinase domain mutations L858R (also called L834R) and ex

212 method enabled biopsy-free profiling of EGFR kinase domain mutations with 92% sensitivity and >99.99%

213 FLT3 inhibitor-resistant AML with secondary kinase domain mutations.

214 focal MET or HGF gene amplification, or MET kinase domain mutations.

215 s suggest that 14-3-3zeta interacts with the kinase domain of ASK1 in close proximity to its active s

216 The intracellular kinase domain of BRI1 is an active kinase and also encap

217 Newman algorithm-based community maps of the kinase domain of cAMP-dependent protein kinase A allow f

218 for ER-associated Bak and interacts with the kinase domain of DAPk1 to form Bik-DAPk1-ERK1/2-Bak comp

219 ion on the catalytic properties of the alpha-kinase domain of Dictyostelium myosin-II heavy chain kin

220 1 mono-methylates lysine 721 in the tyrosine kinase domain of EGFR, and that this methylation leads t

221 c.1966A>G (p.Lys656Glu) within the tyrosine kinase domain of FGFR1, in two affected individuals each

222 ons to probe the activation mechanism of the kinase domain of Fibroblast Growth Factor Receptor (FGFR

223 e to quizartinib induced by mutations in the kinase domain of FLT3, suggesting that these compounds m

224 lso stabilize a distinct conformation of the kinase domain of GRK2 compared with previous complexes w

225 Here we report on the structure of the kinase domain of human NEK1 in its apo- and ATP-mimetic

226 Mutations in the kinase domain of leucine-rich repeat kinase 2 (LRRK2) fo

227 ith genomic rearrangements of MET fusing the kinase domain of MET in-frame to six different N-termina

228 R-induced allelic variation in the conserved kinase domain of MPK6.

229 455, identifying five point mutations in the kinase domain of MPS1 that confer resistance against mul

230 imal region, the transmembrane helix and the kinase domain of PDGFRbeta are involved in dimerization.

231 e discover that Smurf1 directly binds to the kinase domain of PIPKIgamma via its C2 domain while Lysi

232 interacts with or occupies the RBD2 and the kinase domain of PKR, which then prevents PACT binding t

233 -function mutant mouse lacking the guanylate kinase domain of PSD-95 (PSD-95(GK)), we analyzed the co

234 nstrate that the Erk1/2-activated C-terminal kinase domain of Rsk is dispensable for p38-MK2/3 activa

235 All six mutations occurred outside the kinase domain of SIK1 and each of the mutants displayed

236 side of the thylakoid membrane activates the kinase domain of Stt7 on the trans (negative) side, lead

237 endometrial cancer hotspots in the tyrosine kinase domain of the FGFR2 protein, one of which is also

238 to sequences outside of-but adjacent to-the kinase domain of TrkA.

239 we report the 2.2 A crystal structure of the kinase domain of Trl1 from the fungal pathogen Candida a

240 Here we show that the C-terminal kinase domain of TRPM6 is cleaved from the channel domai

241 en mutations in the fibronectin type III and kinase domains of EPHB1 were compared with wild-type EPH

242 idence demonstrating that the phosphorylated kinase domains of IR and IGF1R form a specific dimeric a

243 bserve different structural organizations of kinase domains of Mec1 and Tel1.

244 We show that the C1A and kinase domains of PKCgamma are involved in its soluble d

245 endently of properties of the regulatory and kinase domains of PKDs.

246 owed that TWD1 interacts physically with the kinase domains of the BR receptor kinases BRI1 and BAK1.

247 ermine the functional redundancy between the kinase domains of the four major RIPK family members.

248 demonstrate that KAT2A/2B acetylate the PLK4 kinase domain on residues K45 and K46.

249 the ATP or peptide binding-sites within the kinase domain, or are important for protein stability, s

250 ug resistance mutations were detected in the kinase domain, overexpression of the mutant ALK was toxi

251 Although these cleavages preserve the entire kinase domain, p50 N-LOK displays no kinase activity.

252 ral analysis of the complex between the ASK1 kinase domain phosphorylated at Ser-966 (pASK1-CD) and t

253 LRRK2, this paradigm may be reversed, as the kinase domain phosphorylates its own GTPase domain.

254 domain conformation, resulting in increased kinase domain phosphorylation.

255 I3K p110beta isoform that resides within its kinase domain (PIK3Cbeta(D1067V)).

256 r interactions between the SH3 and guanylate kinase domains play a role in the stability of beta1a wh

257 ere, by analyzing mice with juxtamembrane or kinase domain point mutations that increase PDGFRalpha a

258 dem duplication mutations, 23% FLT3-tyrosine kinase domain point mutations, and 2% both types.

259 vanescent fields reflect the changes in EGFR kinase domain polarization upon ligand binding.

260 t PKR sequence or structural elements in the kinase domain, present in hPKR but absent in rat PKR, ar

261 This interaction holds kinase domains proximal as they "readjust," whereas gene

262 In a much slower second step, the kinase domains rearrange internally.

263 c changes that are propagated throughout the kinase domain remains poorly understood.

264 identified, the catalytic necessity of these kinase domains remains unknown.

265 how PD-linked mutations that lie within the kinase domain result in hPINK1 loss-of-function and prov

266 s with purified cyt b6f and recombinant Stt7 kinase domain show that cyt b6f enhances Stt7 autophosph

267 osphorylated and phosphorylated forms of the kinase domains show no apparent structural change that c

268 al and clinical significance, only the IRAK4 kinase domain structure has been determined among the fo

269 possessing gain of function mutations in the kinase domain such as the most prevalent G2019S mutation

270 roximity-together with the LRR domain-to the kinase domain suggest an intramolecular mechanism for LR

271 proximal as they "readjust," whereas generic kinase domain surface contacts bring them into a catalyt

272 osed of a dual specificity (Ser/Thr and Tyr) kinase domain tethered to a calmodulin-like domain (CLD)

273 novel, contiguous embellishment to the Hrr25 kinase domain that affects Hrr25 conformational dynamics

274 to the acquired point mutations in the FLT3 kinase domain that contribute to FLT3 inhibitor resistan

275 active cation channel with a cytosolic alpha-kinase domain that is critical for embryonic development

276 kinase c-ros oncogene 1 (ROS1), which has a kinase domain that is physiologically related to anaplas

277 We identify mutations in the kinase domain that lead to elevated levels of PI(3,5)P2

278 phosphodiesterase and central polynucleotide kinase domains that heal the broken ends to generate the

279 The phosphorylated IRAK4 kinase domain then forms heterodimers with the IRAK1 kin

280 LT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal tandem duplication (ITD)

281 RE1's ATP-binding pocket and predisposes the kinase domain to oligomerization, activating its RNase.

282 and optogenetic recruitment of the PI3K C2A kinase domain to the TGN-induced deltaR export downstrea

283 ein with separate surfaces of the C-terminal kinase domain, to co-operatively inhibit kinase activati

284 K1 contains a nonarginine-aspartate (non-RD) kinase domain, typically found in plant innate immune re

285 nly occurs in structured domains, and on the kinase domain, ubiquitination is concentrated in regions

286 oiled coil linker and the attached histidine kinase domains undergo a left handed rotation within mic

287 spread among maize germplasm, and the ZmWAK kinase domain underwent functional constraints during ma

288 transmembrane receptors and activating their kinase domains via transphosphorylation.

289 ains at rationally selected locations in the kinase domain, we created the photoswitchable kinases ps

290 Point mutations in the ABL1 kinase domain weaken inhibitor binding and represent the

291 ndem stop codons, UA(1831)GUA(1834)G, in its kinase domain were changed to UG(1831)GUG(1834)G by RNA

292 nsforming growth factor beta receptor type 1 kinase domain were determined by X-ray crystallography.

293 structural consequences throughout the BAK1 kinase domain, whereas glutathionylation of C353 in the

294 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade

295 Moreover, separation of the sensor and kinase domains, which deactivates catalysis, increased t

296 identifies a new set of residues in the Btk kinase domain with high node centrality values indicatin

297 urprisingly, however, replacement of RIPK2's kinase domain with RIPK4's did not complement a nucleoti

298 ic juxtamembrane segment (JM) that links the kinase domain with the extracellular and transmembrane r

299 omain then forms heterodimers with the IRAK1 kinase domain within the Myddosome, leading to its subse

300 Whether the two phosphorylated tyrosine kinase domains within the receptor dimer function indepe